[Future prospects in developing of dengue vaccines]

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Dengue fever, a significant arboviral disease, poses a substantial global health burden, particularly in low-socioeconomic endemic areas.
• Current dengue control strategies primarily rely on vector control measures, as effective antiviral treatments for flaviviruses like dengue are unavailable.
• The development of a safe and effective dengue vaccine is a critical unmet need for disease eradication and public health improvement.

Discussion:

• Several dengue vaccine candidates, including live attenuated, chimeric, inactivated, subunit, and DNA vaccines, are in advanced development stages, aiming to mimic natural infection.
• An ideal dengue vaccine should be tetravalent, providing protection against all four serotypes, be highly immunogenic, reactogenic-free, long-lasting, safe with minimal side effects, cost-effective, and easily administered in a single dose for both adults and children.

Key Insights:

• The absence of specific antiviral drugs for dengue underscores the urgent need for a robust vaccine solution.
• The diverse range of vaccine platforms under investigation highlights the complexity and multifaceted approach to dengue vaccine development.
• Defining the characteristics of an ideal dengue vaccine is essential for guiding research and development efforts towards impactful public health interventions.

Outlook:

• Continued research and development are focused on achieving immunoprophylaxis against dengue virus through innovative vaccine design.
• The ultimate goal is to develop a single-dose, cost-effective vaccine that can be widely implemented to eradicate dengue and reduce its daily impact on affected populations.
• Successful dengue vaccine deployment holds the potential to significantly decrease disease incidence and associated morbidity and mortality globally.